Quantum Capital Management Grows Holdings in DexCom, Inc. (DXCM)

Quantum Capital Management grew its position in DexCom, Inc. (NASDAQ:DXCM) by 16.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,989 shares of the medical device company’s stock after acquiring an additional 10,443 shares during the quarter. Quantum Capital Management owned 0.09% of DexCom worth $3,669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the business. Marble Harbor Investment Counsel LLC increased its stake in DexCom by 36.5% in the 3rd quarter. Marble Harbor Investment Counsel LLC now owns 37,940 shares of the medical device company’s stock worth $1,856,000 after acquiring an additional 10,150 shares during the last quarter. Quantbot Technologies LP increased its stake in DexCom by 62.3% in the 3rd quarter. Quantbot Technologies LP now owns 22,485 shares of the medical device company’s stock worth $1,100,000 after acquiring an additional 8,630 shares during the last quarter. Russell Investments Group Ltd. increased its stake in DexCom by 1,190.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 333,978 shares of the medical device company’s stock worth $16,338,000 after acquiring an additional 308,098 shares during the last quarter. Toronto Dominion Bank increased its stake in DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after acquiring an additional 2,608 shares during the last quarter. Finally, Cabot Wealth Management Inc. increased its stake in DexCom by 68.2% in the 3rd quarter. Cabot Wealth Management Inc. now owns 40,414 shares of the medical device company’s stock worth $1,977,000 after acquiring an additional 16,388 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This story was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.themarketsdaily.com/2017/11/16/quantum-capital-management-grows-holdings-in-dexcom-inc-dxcm.html.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $75.26, for a total value of $123,050.10. Following the completion of the sale, the executive vice president now directly owns 72,395 shares in the company, valued at approximately $5,448,447.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The disclosure for this sale can be found here. Insiders sold a total of 13,964 shares of company stock valued at $948,039 over the last quarter. Company insiders own 1.70% of the company’s stock.

Several research firms have recently weighed in on DXCM. Canaccord Genuity reissued a “buy” rating and set a $90.00 target price on shares of DexCom in a research report on Tuesday, August 22nd. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised DexCom from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Barclays PLC began coverage on DexCom in a research report on Friday, September 15th. They set an “equal weight” rating and a $76.00 target price on the stock. Finally, BMO Capital Markets reissued an “outperform” rating and set a $90.00 target price (down previously from $105.00) on shares of DexCom in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom has an average rating of “Buy” and a consensus target price of $70.69.

Shares of DexCom, Inc. (NASDAQ:DXCM) traded up $0.45 during mid-day trading on Thursday, hitting $52.00. The company’s stock had a trading volume of 1,352,600 shares, compared to its average volume of 1,433,743. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply